Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEO NASDAQ:AMPH NASDAQ:STOK NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.70+0.3%$6.58$3.93▼$7.54$292.04M1.67997,889 shs449,041 shsAMPHAmphastar Pharmaceuticals$27.58+2.2%$25.93$20.39▼$53.96$1.28B0.8561,826 shs574,310 shsSTOKStoke Therapeutics$23.18+0.1%$16.50$5.35▼$24.60$1.27B1.14812,606 shs384,536 shsTLRYTilray Brands$1.22-0.4%$0.94$0.35▼$1.87$1.35B2.0342.74 million shs18.37 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-0.70%-16.84%-20.34%-5.33%+6.57%AMPHAmphastar Pharmaceuticals-0.99%-7.94%-9.49%+6.55%-44.19%STOKStoke Therapeutics-1.03%+4.94%+27.18%+100.17%+57.34%TLRYTilray Brands+3.39%+7.02%+18.45%+218.29%-32.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.70+0.3%$6.58$3.93▼$7.54$292.04M1.67997,889 shs449,041 shsAMPHAmphastar Pharmaceuticals$27.58+2.2%$25.93$20.39▼$53.96$1.28B0.8561,826 shs574,310 shsSTOKStoke Therapeutics$23.18+0.1%$16.50$5.35▼$24.60$1.27B1.14812,606 shs384,536 shsTLRYTilray Brands$1.22-0.4%$0.94$0.35▼$1.87$1.35B2.0342.74 million shs18.37 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-0.70%-16.84%-20.34%-5.33%+6.57%AMPHAmphastar Pharmaceuticals-0.99%-7.94%-9.49%+6.55%-44.19%STOKStoke Therapeutics-1.03%+4.94%+27.18%+100.17%+57.34%TLRYTilray Brands+3.39%+7.02%+18.45%+218.29%-32.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 3.00Buy$19.50242.41% UpsideAMPHAmphastar Pharmaceuticals 2.40Hold$31.6014.57% UpsideSTOKStoke Therapeutics 3.22Buy$25.5710.33% UpsideTLRYTilray Brands 2.33Hold$1.9459.47% UpsideCurrent Analyst Ratings BreakdownLatest ABEO, AMPH, STOK, and TLRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025AMPHAmphastar PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$28.00 ➝ $32.008/25/2025TLRYTilray BrandsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.50 ➝ $2.008/18/2025STOKStoke TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$28.008/18/2025ABEOAbeona TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/15/2025ABEOAbeona TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$19.00 ➝ $20.008/13/2025STOKStoke TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.008/13/2025STOKStoke TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$16.00 ➝ $22.008/12/2025AMPHAmphastar PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$36.008/8/2025AMPHAmphastar PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$30.00 ➝ $25.007/29/2025TLRYTilray BrandsZelman & AssociatesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral7/18/2025STOKStoke TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M83.44N/AN/A$1.01 per share5.64AMPHAmphastar Pharmaceuticals$731.97M1.75$5.06 per share5.45$15.23 per share1.81STOKStoke Therapeutics$36.56M34.74N/AN/A$4.32 per share5.37TLRYTilray Brands$821.31M1.63$0.15 per share8.16$1.40 per share0.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$63.73M$0.708.14N/AN/AN/A89.05%45.64%11/13/2025 (Estimated)AMPHAmphastar Pharmaceuticals$159.52M$2.6710.338.38N/A18.64%20.76%9.68%11/5/2025 (Estimated)STOKStoke Therapeutics-$88.98M$0.8527.25N/AN/A26.25%18.32%15.48%11/4/2025 (Estimated)TLRYTilray Brands-$2.19B-$2.31N/AN/AN/A-265.69%-6.83%-5.45%10/9/2025 (Estimated)Latest ABEO, AMPH, STOK, and TLRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/9/2025Q1 2026TLRYTilray Brands-$0.03N/AN/AN/A$205.75 millionN/A8/14/2025Q2 2025ABEOAbeona Therapeutics-$0.39$1.71+$2.10$1.71$21.71 million$0.40 million8/12/2025Q2 2025STOKStoke Therapeutics-$0.57-$0.40+$0.17-$0.40$31.51 million$13.82 million7/28/2025Q4 2025TLRYTilray Brands-$0.03$0.02+$0.05-$1.30$250.41 million$224.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.096.736.65AMPHAmphastar Pharmaceuticals0.803.292.21STOKStoke TherapeuticsN/A6.986.98TLRYTilray Brands0.202.461.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%AMPHAmphastar Pharmaceuticals65.09%STOKStoke TherapeuticsN/ATLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.40%AMPHAmphastar Pharmaceuticals27.10%STOKStoke Therapeutics9.50%TLRYTilray Brands0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9051.28 million48.51 millionOptionableAMPHAmphastar Pharmaceuticals2,02846.49 million33.90 millionOptionableSTOKStoke Therapeutics10054.80 million49.59 millionOptionableTLRYTilray Brands2,8421.10 billion1.09 billionOptionableABEO, AMPH, STOK, and TLRY HeadlinesRecent News About These CompaniesBest Cannabis Stocks To Consider - September 17th1 hour ago | marketbeat.comTilray stock price sits and waits for Trump cannabis rescheduling3 hours ago | invezz.comITilray Brands Inc. Unveils BC Selects: A New Line of Limited-Edition Premium Cannabis from Broken CoastSeptember 17 at 7:50 AM | quiverquant.comQBroken Coast Cannabis Brand Launches Premium and Limited BC Selects Line and Unveils New Strain “Sprits 26”, Elevates Craft Portfolio with Modern Blue Dream ReleaseSeptember 17 at 7:00 AM | globenewswire.comTilray Brands, Inc. (NASDAQ:TLRY) Receives Consensus Recommendation of "Hold" from AnalystsSeptember 17 at 4:17 AM | marketbeat.comTilray Brands (TLRY) Is Down 5.9% After DOJ Rule SetbackSeptember 16 at 2:11 PM | finance.yahoo.comBest Cannabis Stocks To Watch Now - September 16thSeptember 16 at 1:25 PM | marketbeat.comBreckenridge Brewery Awarded Silver Certification By The Colorado Green Business NetworkSeptember 16 at 10:50 AM | insidermonkey.comBest Canadian Marijuana Stocks for Traders and Investors Right NowSeptember 16 at 10:00 AM | marijuanastocks.comMHop Valley Brewing and Oregon Athletics Announce the Launch of Dang Green IPA, the First Official Craft Beer for the Oregon DucksSeptember 16 at 7:00 AM | globenewswire.comBest Cannabis Stocks To Keep An Eye On - September 15thSeptember 15 at 1:04 PM | marketbeat.comTop Cannabis Stocks To Watch Today - September 14thSeptember 15 at 1:00 PM | marketbeat.comCannabis Stocks To Research - September 13thSeptember 14 at 1:07 PM | marketbeat.comPromising Cannabis Stocks To Consider - September 12thSeptember 13, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Shares Gap Up - Should You Buy?September 13, 2025 | marketbeat.comCannabis Stocks Worth Watching - September 11thSeptember 12, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Shares Gap Down - Here's What HappenedSeptember 12, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Trading Down 3.9% - Should You Sell?September 11, 2025 | marketbeat.comPromising Cannabis Stocks To Follow Today - September 10thSeptember 11, 2025 | marketbeat.comPot Stocks Rallied Hard in August: Is There More to Come?September 10, 2025 | msn.comTilray Brands (NASDAQ:TLRY) Trading Up 1.3% - Here's WhySeptember 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025The Case for Buying NVIDIA Stock Ahead of the Robotics SurgeBy Thomas Hughes | August 20, 2025Tilray's High Hopes: The Catalyst Driving Cannabis StocksBy Jeffrey Neal Johnson | August 21, 2025ABEO, AMPH, STOK, and TLRY Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$5.70 +0.02 (+0.26%) As of 01:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Amphastar Pharmaceuticals NASDAQ:AMPH$27.58 +0.58 (+2.16%) As of 01:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Stoke Therapeutics NASDAQ:STOK$23.18 +0.02 (+0.08%) As of 01:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Tilray Brands NASDAQ:TLRY$1.22 -0.01 (-0.41%) As of 01:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
